Wealth Enhancement Advisory Services LLC Boosts Holdings in Cellebrite DI Ltd. $CLBT

Wealth Enhancement Advisory Services LLC boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 40.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 359,764 shares of the company’s stock after acquiring an additional 103,568 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.15% of Cellebrite DI worth $6,652,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of CLBT. Voss Capital LP increased its position in shares of Cellebrite DI by 34.0% during the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after purchasing an additional 1,306,398 shares in the last quarter. Phoenix Financial Ltd. boosted its position in shares of Cellebrite DI by 153.5% in the 2nd quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock valued at $32,232,000 after purchasing an additional 1,219,958 shares during the period. Handelsbanken Fonder AB grew its stake in Cellebrite DI by 61.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock worth $39,200,000 after buying an additional 931,300 shares during the last quarter. Thematics Asset Management purchased a new position in Cellebrite DI during the 2nd quarter worth approximately $13,919,000. Finally, Qube Research & Technologies Ltd increased its position in Cellebrite DI by 93.7% during the second quarter. Qube Research & Technologies Ltd now owns 1,500,505 shares of the company’s stock worth $24,008,000 after buying an additional 725,679 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on CLBT. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Lake Street Capital increased their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Bank of America raised their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $15.87 on Monday. The stock has a fifty day moving average price of $17.85 and a 200 day moving average price of $16.98. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30. The company has a market cap of $3.80 billion, a PE ratio of 51.19, a P/E/G ratio of 2.21 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The firm had revenue of $126.03 million during the quarter, compared to analyst estimates of $122.98 million. During the same period in the prior year, the firm posted $0.14 earnings per share. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.